A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study - Teresa Gamucci, Laura Pizzuti, Clara Natoli, Lucia Mentuccia, Isabella Sperduti, Maddalena Barba, Domenico Sergi, Laura Iezzi, Marcello Maugeri-Saccà, Angela Vaccaro, Emanuela Magnolfi, Alain Gelibter, Giacomo Barchiesi, Valentina Magri, Loretta D’Onofrio - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Taylor and Francis Group, Cancer Biology & Therapy, 2(20), p. 192-200, 2018

DOI: 10.1080/15384047.2018.1523095

Links

Tools

Export citation

Search in Google Scholar

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

Journal article published in 2018 by Teresa Gamucci, Laura Pizzuti, Clara Natoli, Lucia Mentuccia, Isabella Sperduti, Maddalena Barba, Domenico Sergi, Laura Iezzi, Marcello Maugeri-Saccà, Angela Vaccaro, Emanuela Magnolfi, Alain Gelibter, Giacomo Barchiesi, Valentina Magri, Loretta D’Onofrio and other authors.

Distributing this paper is prohibited by the publisher

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle

Preprint: archiving forbidden

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO